Boehringer Ingelheim and Sino Biopharmaceutical expanded their long-running oncology partnership with a multi-program option and license agreement focused on antibody-drug conjugates (ADCs) and T-cell engagers (TcEs). The deal covers six biologic preclinical programs—five from SBP Group subsidiaries LaNova Medicines and Beijing Tide Pharmaceutical and one additional from within SBP Group’s portfolio—while allowing Boehringer to exercise development and commercialization options after milestone achievements. The collaboration includes $358 million in upfront and near-term payments from Boehringer, with potential total payments of up to $7.0 billion tied to development, regulatory, and commercial milestones, plus tiered royalties on future sales. Boehringer said the expanded scope is intended to broaden its differentiated oncology pipeline spanning cancer cell-directed therapy and immuno-oncology. For SBP Group, the agreement further validates its strategy of supplying early-stage assets and platforms into global pharma development engines, with potential upside contingent on later-stage execution. The immediate market reaction, with SBP shares rising on the news, suggests investor confidence in the scalability of the combined ADC and TcE approach. Overall, the transaction highlights how large pharma continues to deepen platform-based intake of oncology biologics from Asia—seeking faster portfolio expansion while leveraging local discovery and early development capabilities.